Skip to main content

Table 1 Characteristics of the 11 included studies

From: Effect of Buyang Huanwu decoction for the rehabilitation of ischemic stroke patients: a meta-analysis of randomized controlled trials

Study Age (years) Course of disease Sample size (Male/Female) Intervention group Control group Treatment duration
Chang L (2014) 60–70 1–4 y 200 (100/100) NR BHD Piracetam tablet (0.8 g tid) 30 d
Cui H (2016) (63.8 ± 3.4)
(62.4 ± 2.3)
(1.7 ± 0.5) m
(2.2 ± 0.6) m
72 (36/36) (25/11)
(23/13)
BHD Naotong decoction (TCM) 3 m
Jian S (2006) (58.48 ± 9.06)
(56.33 ± 9.13)
18–161 d
22–154 d
76 (40/36) (23/17)
(16/20)
BHD Vinpocetine (5 mg tid) 4 w
Li S (2013) (58.64 ± 4.97)
(59.87 ± 4.54)
(6.38 ± 1.28) m
(6.96 ± 1.59) m
40 (20/20) (11/9)
(13/7)
BHD Maixuekang capsule (CPM, 0.5 g tid) 3 m
Li S (2016) (54.6 ± 13.4)
(53.7 ± 12.5)
(5.01 ± 3.96) y
(4.96 ± 4.01) y
80 (40/40) (17/23)
(20/20)
BHD Vitamin E (200 mg tid), Aspirin (100 mg qd), Nimodipine (30 mg tid), Venoruton tablet (20 mg tid) 3 m
Luo K (2016) (65.1 ± 2.9)
(65.0 ± 3.0)
(0.6 ± 0.2) y
(0.8 ± 0.2) y
80 (40/40) (21/19)
(22/18)
BHD Conventional western medicine treatment, Nutritional metabolism therapy 30 d
Xu S (2015) (62.2 ± 1.1)
(63.1 ± 1.2)
(6.4 ± 0.4) m
(6.1 ± 0.2) m
60 (30/30) (16/14)
(15/15)
BHD Nimodipine, Vitamin E, Venoruton tablet 3 m
Yan Y (2015) (60.5 ± 4.8)
(61.2 ± 4.5)
(5.6 ± 1.2) m
(6.2 ± 1.3) m
82 (41/41) (25/16)
(23/18)
BHD Aspirin (100 mg qd), Nimodipine (30 mg tid), Venoruton tablet (20 mg bid) 3 m
Ying W (2016) (54.10 ± 4.7)
(54.42 ± 5.6)
16 d—4 m
20 d—5 m
194 (97/97) (51/46)
(62/35)
BHD Aspirin (100 mg qd), Clopidogrel (75 mg qd) 30 d
Zhang D (2013) (58.20 ± 10.13)
(59.41 ± 9.84)
(4.58 ± 5.29) y
(4.79 ± 5.15) y
120 (60/60) (29/31)
(32/28)
BHD Naoxintong capsule (CPM, 4 capsules tid) 6 m
Zhang H (2018) (63.65 ± 5.35)
(63.55 ± 5.77)
2 w—6 m 80 (30/50) (16/14)
(33/17)
BHD Peiyuan Tongnao capsule (CPM, 3 capsules tid) 2 m
  1. NR: not reported; BHD: Buyang Huanwu decoction or modified Buyang Huanwu decoction; CPM: Chinese patent medicine; CE: clinical efficacy; NIHSS: National Institute of Health stroke scale; ADLs: activities of daily living; AE: adverse events